Endoscopic recommendations for colorectal cancer screening and surveillance in patients with inflammatory bowel disease: Review of general recommendations

Table 1 Consensus of reviewed scientific societies

Abbreviations	Scientific society
ECCO	European Crohn’s and Colitis Organisation
NZGG	New Zealand Guidelines Group
BSG	The British Society of Gastroenterology
ACPGBI	The Association of Coloproctology for Great Britain and Ireland
CCA	Cancer Council Australia
ASGE	American Society for Gastrointestinal Endoscopy
ESGE	European Society of Gastrointestinal Endoscopy
ACG	American College of Gastroenterology
NASPGHAN	North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition
CCFA	Crohn’s and Colitis Foundation of America
NICE	National Institute for Health and Clinical Excellence
WGO	World Gastroenterology Organisation
AGA	American Gastroenterological Association
CAG	Canadian Association of Gastroenterology
Asia-Pacific	Asia Pacific Association of Gastroenterology
ACOG	Asociación Colombiana de Gastroenterología
SVG	Sociedad Venezolana de Gastroenterología
JPN	Research Group of Intractable Inflammatory Bowel Disease. Japan

Table 2 Risk factors for the development of colorectal cancer in patients with inflammatory bowel disease and recommended surveillance[1-7,9,11,13-15,17,18,24]

	High risk	Intermediate risk	Low risk
Risk factors	PSC Extensive involvement Moderate-severe active inflammation sustained over time (endoscopic or histological) First-degree relative with CRC at an age of less than 50 Stenosis or dysplasia detected during the previous five years Appearance of IBD at a young age1 If ileo-anal pouch: Dysplasia Previous CRC PSC Type C mucosa in the pouch	Extensive colitis with mild or moderate sustained inflammatory activity (endoscopic or histological) Inflammatory polyps First-degree relative with CRC at an age of above 50	Other factors different from high and intermediate risk
Surveillance	Annual	Every three years	Every five years

¹BSG[5], CCFA[11], WGO[14] and SVG[18]. CRC: Colorectal cancer; IBD: Inflammatory bowel disease; PSC: Primary sclerosing cholangitis.

Table 3 SCENIC international consensus

Term	Definition
1 Visible dysplasia	Dysplasia identified on targeted biopsies from a lesion visualised at colonoscopy
Polypoid	Lesion protruding from the mucosa into the lumen ≥ 2.5 mm
Pedunculated	Lesion attached to the mucosa by a stalk
Sessile	Lesion not attached to the mucosa by a stalk: Entire base is contiguous with the mucosa
Nonpolypoid	Lesion with little (< 2.5 mm) or no protrusion above the mucosa
Superficially elevated	Lesion with protrusion but < 2.5 mm above the lumen (less than the height of the closed cup of a biopsy forceps)
Flat	Lesion without protrusion above the mucosa
Depressed	Lesion with at least a portion depressed below the level of the mucosa
General descriptors
Ulcerated	Ulceration (fibrinous-appearing base with depth) within the lesion
Border
Distinct border	Lesion’s border is discrete and can be distinguished from surrounding mucosa
Indistinct border	Lesion’s border is not discrete and cannot be distinguished from surrounding mucosa
2 Invisible dysplasia	Dysplasia identified on random (non-targeted) biopsies of colon mucosa without a visible lesion

Terminology for reporting findings[23].